Among infectious agents, HHV-6 was found to be an independent risk factor for thrombotic microangiopathy (TMA) and only HHV-6 infection was associated with TMA-related mortality.
Viral reactivation may be one cause of febrile neutropenia in chemotherapy patients
HHV-6 was the most prevalent virus in febrile neutropenia episodes among pediatric patients
The effects of HHV-6B infection on immune checkpoint inhibition
HHV-6B infection of primary monocytes induces cell-associated and soluble PD-L1 production, increased intracellular ROS and activation of STAT1 and STAT3 pathways
Adult patients with lower levels of anti-HHV-6 IgG are significantly more likely to experience HHV-6 reactivation following cord blood transplant
Patients with low levels of HHV-6 antibodies might benefit from treatment from IVIG or novel neutralizing antibodies before cord blood transplantation
Anemia: Deformation of erythroblasts caused by HHV-6
A group from Japan has found that the deformation of erythroblasts seen in transient erythroblastopenia of childhood, is caused by HHV-6. Erythroblasts are progenitor cells in the bone marrow, necessary for the production of red blood cells.